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a b s t r a c t
Cardiac magnetic resonance (CMR) with its higher spatial resolution is considered the gold
standard for evaluating ventricular mass, volumes, and ejection fraction. CMR can be used
for accurate diagnosis of several conditions, especially cardiomyopathies. The purpose of
this article is to review the utility of CMR in the diagnosis and management of nonischemic
cardiomyopathies. We have reviewed both common and rare types of nonischemic cardio-
myopathies in detail and elaborated on the speciﬁc CMR ﬁndings in each. We believe that
CMR is an invaluable tool, not only in differentiating nonischemic from ischemic cardio-
myopathy, but also in aiding the accurate diagnosis and management of the subtype of
nonischemic cardiomyopathy. CMR should routinely be integrated in the diagnostic workup
of various cardiomyopathies.
Published by Elsevier B.V. on behalf of Cardiological Society of India.
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Cardiac magnetic resonance (CMR) is considered to be the gold
standard for evaluating ventricular mass, volumes, and
ejection fraction. CMR has an advantage in that it is not
limited by poor acoustic windows, which can often limit
echocardiographic studies, thereby enabling diagnosis of
pathologies, which are otherwise not readily recognized by
echocardiography. CMR can be used for assessing many
pathologies, including aortic disease, coronary artery disease
(CAD), cardiomyopathies, pericardial disease, and congenital
heart disease.1 The purpose of this article is to review the
utility of CMR in diagnosis and management of nonischemic
cardiomyopathies.* Corresponding author.
E-mail address: raj@shc.arizona.edu (R. Janardhanan).
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0019-4832/Published by Elsevier B.V. on behalf of Cardiological Societ2. Classiﬁcation of cardiomyopathies
The current AHA classiﬁcation of cardiomyopathies divides
them into primary, which affect only the heart, and secondary,
a much larger group in which myocardial involvement is part
of a systemic (multiorgan) generalized disease process.
Further subclassiﬁcation is as follows2:
1. Primary
a. Genetic
i. Hypertrophic (obstructive) cardiomyopathy (HCM or
HOCM)
ii. Arrhythmogenic right ventricular cardiomyopathy/
Dysplasia (ARVC/D)y of India.
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iv. Glycogen storage disorders
v. Conduction defects
vi. Mitochondrial myopathies
vii. Ion channel disorders (e.g. Brugada's, Long QT)
b. Mixed
i. Dilated cardiomyopathy
ii. Restrictive cardiomyopathy
c. Acquired
i. Inﬂammatory (myocarditis)
ii. Stress provoked (Takotsubo)
iii. Peripartum
iv. Tachycardia induce
2. Secondary
a. Inﬁltrative, e.g. amyloidosis
b. Storage, e.g. hemochromatosis, Fabry's disease
c. Toxicity, e.g. alcohol, cocaine
d. Endomyocardial, e.g. endomyocardial ﬁbroelastosis,
Loefﬂer's syndrome
e. Inﬂammatory, e.g. sarcoidosis
f. Endocrine, e.g. DM, thyroid disorders, acromegaly,
pheochromocytoma
g. Cardiofacial
h. Neuromuscular/neurological, e.g. Duchenne-Becker,
Friedrich's ataxia
i. Nutritional deﬁciencies
j. Autoimmune/collagen e.g. RA, SLE
k. Electrolyte imbalance
l. Consequence of cancer therapy e.g. anthracyclines, such
as doxorubicin, or alkylating agents, such as cisplatin
and cyclophosphamide
3. Differentiating nonischemic from ischemic
cardiomyopathy
While attempting to diagnose the etiology of cardiomyopathy,
it is important to exclude CAD as the etiology, given the
differences in management. CMR technique of late gadolinium
enhancement (LGE) becomes valuable in establishing the
proper diagnosis. Gadolinium chelates are extracellular
contrast agents that cannot cross myocyte cell membranes.3
Normal myocardium is densely packed with viable myocytes
that do not permit entrance of gadolinium into the cell; thus
there is little gadolinium enhancement of normal myocardi-
um. However, in the setting of an acute myocardial infarction,
myocardial cell membrane rupture will allow gadolinium to
freely diffuse into the cell3 resulting in gadolinium hyper-
enhancement. The necrosis begins in the subendocardium
and grows toward the epicardial area near the occluded
artery.3 In chronic myocardial infarction, myocytes get
replaced with collagenous scar tissue in the subendocardial
region leading to increased gadolinium concentration and
hyperenhancement in the subendocardium.3 Thus, ischemic
cardiomyopathy tends to cause LGE in the subendocardium or
transmurally and follows a vascular distribution, which lies in
stark contrast to nonischemic cardiomyopathy, which gener-
ally does not correspond to any particular coronary artery
distribution and is often located in the midwall or epicardialregions.4 Therefore, the pattern of LGE can be used to
differentiate between cardiomyopathies of ischemic and
nonischemic etiologies.
4. Hypertrophic cardiomyopathy
Transthoracic echocardiography (TTE) is considered the ﬁrst
line imaging modality for patients with hypertrophic cardio-
myopathy (HCM). However, CMR can help in diagnosing
variant types of HCM, including apical (Yamaguchi's) and
lateral wall hypertrophies, otherwise not detected by TTE.5
CMR also has high accuracy in wall thickness measurements,
which has important prognostic value. Cine-CMR with ﬂow
velocity encoding can be utilized to evaluate the ﬂow
dynamics and dynamic obstruction of the LV outﬂow tract
in such patients. Several patterns of LGE have been described
in HCM, which demonstrate areas of ﬁbrosis.6 LGE has been
associated with increased risk of re-entrant tachycardias,
ventricular tachycardia, and sudden cardiac death.6
5. ARVC/D
ARVC/D is an inherited condition characterized pathologically
by ﬁbrofatty replacement of the ventricular wall, primarily RV,
and clinically by life-threatening ventricular arrhythmias,
heart failure, and sudden cardiac death.7 The 2010 revised task
force criteria is used for diagnosis of ARVC,8 which includes
parameters for regional RV dysfunction, RV volume, and RV
global dysfunction.
6. Left ventricular noncompaction (LVNC)
LVNC, also known as left ventricular hypertrabeculation, is a
congenital morphological disorder due to an arrest in the
normal process of myocardial compaction during develop-
ment, resulting in persistent prominent ventricular trabecula-
tions and deep intertrabecular recesses. Diagnosis is based on
clinical and morphological criteria. Diagnosis is usually
established by TTE, but when imaging is suboptimal, CMR
can be utilized. CMR criteria for diagnosis of LVNC include
noncompacted to compacted myocardial thickness ratio of
>2.3 (sensitivity, speciﬁcity, and positive and negative pre-
dictions of 86%, 99%, 75%, and 99%, respectively9), and
trabeculated LV mass >20 percent of global LV mass
(sensitivity of 94% and speciﬁcity of 94%).
7. Myocarditis
Myocarditis is an inﬂammation of the myocardium that can be
caused by a variety of etiologies, commonly viral, but also
toxins, drugs, and autoimmune processes.
Findings in CMR include myocardial edema, wall motion
abnormalities, and patchy myocardial LGE. Tissue edema is
best visualized in T2-weighted spin-echo CMR images.10 LGE in
myocarditis is usually patchy, and involves the subepicardial
regions.10 Since edema, and not ﬁbrosis, is the cause for LGE in
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decreases with time. When both T2-weighted imaging and LGE
were used in tandem for evaluation of patient's for myocardi-
tis, the sensitivity, speciﬁcity, and diagnostic accuracy have
been noted to be 76%, 95.5%, and 85%, respectively.10
8. Takotsubo cardiomyopathy
Takotsubo cardiomyopathy (stress cardiomyopathy, apical
ballooning syndrome, broken heart syndrome) is a transient
left ventricular ballooning syndrome that occurs in the
absence of CAD, usually after emotional stress. The pathogen-
esis is thought to involve increased circulating catecholamines
and exaggerated sympathetic stimulation. While CMR can
help in diagnosis of Takotsubo cardiomyopathy, it is important
to note that a coronary angiogram that demonstrates no CAD
is often required for deﬁnitive diagnosis.11
CMR will demonstrate apical ballooning and wall motion
abnormalities, including apical akinesis. An important feature
in Takotsubo cardiomyopathy is that LGE is absent,12 which
helps differentiate it from ACS (subendocardial enhancement)
and myocarditis (patchy subepicardial enhancement).
9. Amyloidosis
Amyloidosis refers to an uncommon condition that results
from systemic or organ speciﬁc extracellular deposition of
insoluble ﬁbrillar proteins. The percentage of amyloid patients
with cardiac involvement depends on the type of amyloidosis,
with cardiac involvement most common in primary/AL (up to
50%), familial/ATTR (10–50%), and secondary/AA (<5%) types.
While evidence of amyloid deposits in the myocardium can be
noted on ECG (low voltage in the limb leads), or echocardiog-
raphy (increased LV wall thickness, small cavity size, diastolic
dysfunction, biatrial enlargement, and pericardial effusion),
CMR with LGE has been shown to have greater sensitivity and
speciﬁcity than TTE. Cardiac amyloidosis appears as global
subendocardial myocardial hyperenhancement on LGE. CMR
with LGE has been reported to have sensitivity, speciﬁcity,
positive predictive, and negative predictive values of between
86–88%, 86–90%, 88–95%, and 67–90%, respectively.13
10. Iron overload
Iron deposition in the myocardium secondary to iron overload
can occur due to either primary (genetic) hemochromatosis or
secondary (transfusion dependent) iron overload. CMR can
detect myocardial iron deposits through T2-star (T2*) tech-
nique, in which the affected myocardium will appear dark
(reduced T2*).14 An abnormally dark liver (due to iron
deposition) can also be noted if included in the imaging
window. It is also important to note that none of the other
markers of iron overload, such as serum iron, ferritin, or liver
iron are accurate predictors of myocardial iron deposition.
This is especially important because cardiomyopathy second-
ary to iron overload is reversible if chelation therapy is
initiated early, and the type of chelation therapy agent useddepends on whether the prime target is extraction of iron from
the heart or the liver.
11. Fabry's disease
Fabry's disease is an X-linked inherited disorder of lysosomal
metabolism resulting in excess deposits of glycospingolipids
within multiple organs. Cardiac manifestations of Fabry's
disease include LV hypertrophy and ﬁbrosis. CMR can
demonstrate ﬁndings that are speciﬁc to Fabry's disease. In
noncontrast T1 mapping, patients with Fabry's disease have
lower septal T1, which helps differentiate from other causes of
LVH, including hypertensive heart disease, aortic stenosis,
amyloidosis, and HCM.15 T1 is inversely proportional to wall
thickness (hypertrophy) and was abnormal even in patients
with Fabry's disease who did not have LVH.15 The same study
also showed pseudonormalization or elevation of T1 in the left
ventricular inferolateral wall, correlating with the presence or
absence of LGE.15 This was consistent with the pattern of LGE
that is commonly seen in Fabry's disease: mesocardic and
subepicardic areas of the basal and inferolateral segments of
the left ventricle.
12. Cocaine/alcohol
Cocaine causes cardiac toxicity through ischemia (coronary
vasospasm) and inﬂammation (hypersensitivity to cocaine/
adulterants). Cocaine-induced cardiomyopathy is suspected
when a strong history of cocaine abuse is present. CMR with
tagging will show regional LV dysfunction, especially diastolic
dysfunction. One study showed myocardial involvement
detected on CMR in 83% of chronic cocaine users with
manifestations, including edema, and LGE suggesting areas
of ﬁbrosis along both ischemic and nonischemic patterns,16
although the long-term prognostic implications of these
ﬁndings are unclear.
Alcohol through multiple mechanisms also causes dilated
cardiomyopathy. Features, such as LV dilation, reduced wall
thickness, and systolic dysfunction, can be easily identiﬁed.
Appropriate diagnosis is important as alcohol cessation can
improve ejection fraction in 50% of affected patients while
continued alcohol use will cause further decline in LV
function.17 CMR is valuable when echocardiographic images
are suboptimal; however, there are no features that distin-
guish alcoholic cardiomyopathy from other cardiomyopa-
thies.17
13. Hypereosinophilic syndrome and
endomyocardial ﬁbrosis
Hypereosinophilic syndrome (HES) is characterized by in-
creased eosinophils, which can be primary (myeloid or
eosinophilic neoplasm), secondary (parasitic infections i.e.
Loefﬂer's syndrome, or other nonstem cell tumors), or
idiopathic. Endomyocardial ﬁbrosis (EMF) is a disease char-
acterized by ﬁbrosis of the apical endomyocardium. The
cardiac manifestations of EMF are similar to HES; however,
Fig. 1 – Cardiac sarcoidosis: Red arrows demonstrate areas of sub-epicardial LGE in the basal and lateral segments of the left
ventricle in the 4-chamber view (A) and the basal short-axis view (B).
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frequently.
Regardless of etiology, both HES and EMF present similarly
in cardiac imaging. CMR ﬁndings include LGE in the sub-
endocardial surfaces of areas affected by ﬁbrosis, obliteration
of the ventricular apices, occasional thrombus formation in
the apices, and restrictive cardiomyopathy.18
14. Sarcoidosis
The exact incidence of cardiac involvement in sarcoidosis is
unclear. Among patients with sarcoidosis, the prevalence of
cardiac involvement, as noted among studies, has varied
from 5% to 20%.19 Clinical manifestations include heart
block, arrhythmias, restrictive cardiomyopathy, heart fail-
ure, and sudden cardiac death. Guidelines for diagnosis
established by the Japan Society of Sarcoidosis and other
Granulomatous Disorders rely on histological evidence, ECG
abnormalities, echocardiographic abnormalities, and LGE on
CMR.
CMR has been shown to have high sensitivity and
speciﬁcity in detecting cardiac involvement in sarcoidosis.
LGE CMR will demonstrate mesocardial or subepicardial
enhancement with predilection for the basal and lateral
segments of the left ventricle (Fig. 1). In addition, the presence
of LGE in cardiac sarcoidosis has been shown to have
prognostic value, with an increased risk of MACE and cardiac
death.20 Additional ﬁndings noted on CMR include regional
wall motion abnormalities on cine-CMR, and inﬂammation
and edema in the acute phase on T1-weighted images.
15. Other diseases
Many other disease processes can cause secondary cardiomy-
opathy. However, as their ﬁndings are nonspeciﬁc they will be
discussed brieﬂy here. Endocrine disorders, such as diabetes
mellitus, thyroid diseases, pheochromocytoma, and growth
hormone excess, are all associated with dilated cardiomyopathy.Cushing's syndrome commonly presents as HCM, but can on
occasion present with dilated cardiomyopathy. Thiamine
deﬁciency can also cause high output cardiac failure (wet beri-
beri) and eventual dilated cardiomyopathy. Duchenne's muscu-
lar dystrophy and chemotherapeutic agents, such as doxorubi-
cin, also cause dilated cardiomyopathy. In all the above noted
diseases, CMR can show hypertrophic or dilated cardiomyopa-
thy, and LGE in areas of ﬁbrosis, but the patterns are not speciﬁc
to any disease.
16. Conclusion
CMR is an invaluable tool, not only in differentiating
nonischemic from ischemic cardiomyopathy, but also in
aiding the accurate diagnosis of the subtype of nonischemic
cardiomyopathy. CMR should routinely be integrated in the
diagnostic workup of various cardiomyopathies.
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